Mara Aspinall is a healthcare industry leader and pioneer committed to active civic involvement. She is Managing Director of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest. Aspinall also heads Health Catalysts Group, a consulting firm that also publishes the popular Health Catalysts Diagnostics Year in Review and the COVID Weekly Testing Newsletter. In her role as an advisor to The Rockefeller Foundation on COVID diagnostics, Aspinall is co-author of the Foundation’s national reports on COVID and heads the implementation of the National Testing Action Program for K-12 School COVID Testing. Aspinall is passionate about education on diagnostics, genomics and personalized medicine. To that end, she co-founded the School of Biomedical Diagnostics at Arizona State University, where she is Professor of Practice. It is the first school dedicated to diagnostics as an independent discipline.

Aspinall served as President and CEO of Ventana Medical Systems, now Roche Tissue Diagnostics. Previously, she was President of Genzyme Genetics and Genzyme Pharmaceuticals. Aspinall sat on the US Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in the Obama and Bush administrations. Aspinall is also certified in Cybersecurity Board Oversight from Carnegie Mellon University.

Mara G. Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Bio Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE and one of Women Inc.’s Most Influential Corporate Board Directors. Ms. Aspinall holds an MBA from Harvard Business School and a BA from Tufts University. She is a member of the Board of Directors of Abcam plc, Allscripts, Castle Biosciences, DA32 Life Science Tech Acquisition Corp, OraSure Technologies and Blue Cross Blue Shield Arizona.